Toggle Contrast

Publication archive

  • Cancer Vanguard Evaluation. As part of the national Cancer Vanguard, RM Partners worked with external evaluators from Technopolis Group and Optimity Advisors to determine the impact of its work on cancer outcomes and patient experience; the value delivered across all three Vanguard partners; and whether the work can be replicated. The purpose was not to determine a ‘one size fits all’ model of care but rather to identify opportunities to learn from the work of the Vanguard and spread this learning nationally amongst the other 16 Cancer Alliances. There is also an Executive Summary and an Illustrative Summary.
  • Ipsos Mori early diagnosis interventions evaluation November 2019. An external evaluation of the RM Partners Transformation Fund intervention projects by Ipsos Mori and York Health Economics Consortium has demonstrated our success in delivering improvements in earlier detection and faster diagnosis of cancer.
  • Frontier Economics early diagnosis interventions evaluation June 2020. An external evaluation of the RM Partners early diagnosis interventions programme by Frontier Economics and NatCen Social Research, has demonstrated our success in improving cancer services and developing a strong network of organisations.
  • RM Partners Annual Review 2017/18. The RM Partners Annual Review celebrates our transformational cancer work across west London. The review contains a number of examples that illustrate the positive impact our work is  having on improving care and experience for people affected by cancer.
  • RM Partners Annual Review 2018/19. RM Partners Annual Review 2018/19 showcases our projects looking at improving early detection, and enabling faster diagnosis and treatment. Additionally, with more patients than ever living with and beyond cancer, we feature our work aimed at supporting health and well-being which in turn can help to optimise quality of life.

In October 2015 the national Cancer Vanguard was established to support the delivery of the key outcomes from the National Cancer Strategy.

The Cancer Vanguard was a partnership led by The Christie NHS Foundation Trust, The Royal Marsden NHS Foundation Trust, and University College London Hospitals NHS Foundation Trust.

The project was completed in 2018.

Information from the Cancer Vanguard website has been archived and can be found here: